[/toggle]

Cytokinetics (CYTK) has gained more than 20% in the last one month. I recently covered CYTK in an article, noting that it is a high risk high reward opportunity. CYTK has seen mixed results from ALS, positive but early-stage results from the cardiac program. However, the company does have decent amount of cash, enough for 2 years of burn, and a 3-shot-on-goal hand to bet on. Despite the recent rally, it is still attractively valued in my opinion.

Ascendis Initiates Phase 3 Study of Lead Product Candidate- Ascendis Pharma (ASND) announced that it has commenced a Phase 3 clinical trial, called heiGHt, evaluating lead product candidate TransCon Growth Hormone for the treatment of children with growth hormone deficiency (GHD). The trial design mirrors its successful Phase 2 study. The study will enroll around 150 treatment-naive children with GHD. The primary endpoint of the study is height velocity after 12 months of treatment. The study is expected to be completed in December 2018.

BioCryst Does First Subject in Mid-Stage Study of BCX7353- BioCryst Pharmaceuticals (BCRX) announced that the first subject has been dosed in its two-part Phase 2 clinical trial, APeX-1, evaluating next-generation killikrein inhibitor BCX7353 for the treatment of hereditary angioedema (HAE). The study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of BCX7353 in ~50 HAE patients. Part 1 of the study will randomize subjects 1:1 to receive either a once-daily oral dose of 350 mg of BCX7353 or placebo for four weeks. Part 2 of the study will characterize the dose responses in 14 additional patients who will be randomized to receive either 250 mg or 125 mg of BCX7353 once daily or placebo.

Nymox Provides Update on Fexapotide- Nymox Pharmaceutical (NYMX) shares surged on Thursday after the company announced that it expects to file a marketing application (presumably in the U.S.) within the next two quarters seeking approval of fexapotide for the treatment of men with an enlarged prostate, called benign prostate hyperplasia or BPH. In addition, the company said it does not envision needing more cash for the pre-marketing development of fexapotide (it will need new capital for commercialization, though). It intends to partner with a larger company once fexapotide is approved, provided satisfactory terms can be agreed upon.

No approvals to report.

No patents to report.

Allergan (AGN) announced that it has entered into a deal to acquire privately held ForSight VISION5 for $95M in upfront cash plus an undisclosed launch milestone payment related to its lead development program, a peri-ocular ring designed for extended drug delivery and lowering elevated intraocular pressure (IOP) in patients with glaucoma. ForSight's lead candidate, called the Bimatoprost Ring, is a non-invasive product that rests on the surface of the eye under the eyelid.

Alimera Sciences (ALIM) announced a secondary offering of 18 million shares at $1.40 per share. Underwriters to the offering have been granted an option to purchase an additional 900,000 shares to cover for over-allotment, if any.

Amarin (AMRN) announced the pricing of its secondary offering of 21 million ADSs at $2.85 per ADS. The offering is expected to close on August 16th.

No IPOs to report.

Elite Pharmaceuticals (ELTP) broke even in its first quarter. The company reported revenue of $3.27 million, up 51.4% on a year-over-year basis.

Tenax Therapeutics (TENX) reported a loss of $0.17 per share in its second quarter, beating consensus forecast by a penny. The company ended the quarter with $29.5 million in cash on its balance sheet.

Histogenics (HSGX) reported a loss of $0.61 per share in its second quarter, missing consensus forecast by a penny. The company ended the quarter with $15.9 million in cash and cash equivalents on its balance sheet.
Seres (MCRB) reported a loss of $0.70 per share in its second quarter. The company reported revenue of $3 million in the second quarter.

Neos Therapeutics (NEOS) reported a loss of $1.65 per share in its second quarter, missing consensus forecast by 28 cents. The company reported revenue of $1.49 million, up 0.7% on a year-over-year basis. Revenue missed consensus forecast by $0.39 million.

RXi Pharmaceuticals (RXII) reported a loss of $0.34 per share in its second quarter, beating consensus forecast by 2 cents. The company ended the quarter with $5.8 million in cash, cash equivalents and short-term investments of approximately $5.8 million on its balance sheet.

Akers Biosciences (AKER) reported a loss of $0.19 per share in its second quarter. The company reported revenue of $0.96 million, down 1% on a year-over-year basis.
Voyager Therapeutics (VYGR) reported a loss of $0.37 per share in its second quarter. The company reported revenue of $3.72 million, down 24.1% on a year-over-year basis.

Recro Pharma (REPH) reported a loss of $0.83 per share in its second quarter, missing consensus forecast by 5 cents. The company reported revenue of $17.28 million, down 7.4% on a year-over-year basis. Revenue beat consensus forecast by $1.85 million.

Soligenix (SNGX) broke even in its second quarter. The company reported revenue of $3.2 million in its second quarter, up 190.9% on a year-over-year basis.

BioLineRx (BLRX) reported a loss of $0.07 per share in its second quarter, in-line with the consensus forecast. The company ended the quarter with $3.9 million in cash and cash equivalents on its balance sheet.

Aclaris Therapeutics (ACRS) reported a loss of $0.62 per share in its second quarter. The company ended the quarter with $94 million in cash, cash equivalents and marketable securities on its balance sheet.

Zynerba Pharmaceuticals (ZYNE) reported a loss of $0.70 per share in its second quarter. The company ended the quarter with $32.1 million in cash and cash equivalents on its balance sheet.

Brainstorm Cell Therapeutics (BCLI) reported a loss of $0.05 per share in its second quarter, beating consensus forecast by 13 cents. The company ended the quarter with $11.5 million in cash, cash equivalents and short-term deposits on its balance sheet.

Neothetics (NEOT) reported a loss of $0.19 per share in its second quarter. The company ended the quarter with $21.5 million in cash and cash equivalents on its balance sheet.

Dimension Therapeutics (DMTX) reported a loss of $0.49 per share in its second quarter. The company reported revenue of $2.37 million, up 36.2% on a year-over-year basis.

Rock Creek Pharmaceuticals (RCPI) reported a loss of $0.04 per share in its second quarter.

Reata Pharmaceuticals (RETA) reported a loss of $0.05 per share in its second quarter. The company reported revenue of $12.37 million, flat on a year-over-year basis.

Cellectar Biosciences (CLRB) reported loss from operations of $2.3 million. The company ended the quarter with $7.9 million in cash and cash equivalents on its balance sheet.

OncoCyte (OCX) reported a loss of $0.10 per share in its second quarter. The company ended the quarter with $4 million in cash and equivalents on its balance sheet.

Cidara Therapeutics (CDTX) reported a loss of $0.85 per share in its second quarter, missing consensus forecast by 9 cents. The company ended the quarter with $87.1 million in cash, cash equivalents and short-term investments on its balance sheet.

Neuralstem (CUR) reported a loss of $0.04 per share in its second quarter, beating consensus forecast by a penny. The company ended the quarter with $11.12 million in cash and equivalents on its balance sheet.

Catabasis Pharmaceuticals (CATB) reported a loss of $0.61 per share in its second quarter, beating consensus forecast by 4 cents. The company ended the quarter with $42.8 million in cash and cash equivalents on its balance sheet.

ImmuCell (ICCC) broke even in its second quarter. The company reported revenue of $2.4 million, up 22.4% on a year-over-year basis.

BioLife Solutions (BLFS) reported a loss of $0.11 per share in its second quarter, missing consensus forecast by 2 cents. The company reported revenue of $2 million, up 33.3% on a year-over-year basis. Revenue missed consensus forecast by $0.01 million.

NovaBay (NBY) reported a loss of $0.36 per share in its second quarter, missing consensus forecast by 6 cents. The company reported revenue of $2.7 million, up 167.3% on a year-over-year basis. Revenue beat consensus forecast by $0.94 million.

Applied DNA Sciences (APDN) reported a loss of $0.14 per share in its third quarter, missing consensus forecast by 3 cents. The company reported revenue of $0.65 million, down 71.4% on a year-over-year basis. Revenue missed consensus forecast by $0.82 million.

Opexa Therapeutics (OPXA) reported a loss of $0.30 per share in its second quarter, missing consensus forecast by 7 cents. The company reported revenue of $0.73 million, in-line with the consensus forecast. Revenue was flat on a year-over-year basis.

AveXis (AVXS) reported a loss of $0.68 per share in its second quarter. The company ended the quarter with $131.4 million in cash and cash equivalents on its balance sheet.

Pernix Therapeutics (PTX) reported a loss of $0.47 per share in its second quarter. The company reported revenue of $36.7 million, down 21.9% on a year-over-year basis.

Company (Ticker) Brokerage Action Recommendation Price Target My Price Target
Acura Pharmaceuticals (ACUR) FBR & Co. Reiterate Buy

$10

N/A
Akebia Therapeutics (AKBA) JMP Securities Reiterate Market Perform

$16

N/A
Amphastar Pharmaceuticals (AMPH) Piper Jaffray Cos. Reiterate Overweight

$22

N/A
Argos Therapeutics (ARGS) FBR & Co. Price Target Cut Outperform From $14 to $13

$10.30

AstraZeneca (AZN) Beaufort Securities Reiterate Hold N/A N/A
Brainstorm Cell Therapeutics (BCLI) Maxim Group Price Target Set Buy

$5

N/A
Bellerophon Therapeutics (BLPH) Cowen and Company Reiterate Buy N/A N/A
Bristol-Myers Squibb (BMY) Sanford C. Bernstein Price Target Cut Market Perform From $79 to $65 N/A
Bristol-Myers Squibb (BMY) Berenberg Bank Downgrade/Price Target Cut From Buy to Hold From $80 to $70 N/A
Bio-Path Holdings (BPTH) Rodman & Renshaw Price Target Set Buy

$5

N/A
Cara Therapeutics (CARA) Cantor Fitzgerald Reiterate Buy N/A N/A
Coherus Biosciences (CHRS) Barclays Plc Reiterate Buy

$46

N/A
Celldex Therapeutics (CLDX) Jefferies Group Price Target Raised Hold From $4 to $5 N/A
Collegium Pharmaceutical (COLL) Piper Jaffray Cos. Price Target Set Buy

$23

N/A
Depomed (DEPO) Cantor Fitzgerald Reiterate Buy N/A

$30

Dimension Therapeutics (DMTX) Canaccord Genuity Price Target Set Buy

$20

N/A
Eiger Biopharmaceuticals (EIGR) Wedbush Reiterate Outperform

$36

N/A
Amicus Therapeutics (FOLD) Chardan Capital Price Target Set Buy

$15

N/A
Galectin Therapeutics (GALT) FBR & Co. Reiterate Buy N/A N/A
Gilead Sciences (GILD) RBC Capital Markets Price Target Set Buy

$105

$130

GlaxoSmithKline (GSK) Shore Capital Reiterate Hold N/A N/A
Heron Therapeutics (HRTX) Leerink Swann Price Target Set Buy

$33

N/A
Histogenics (HSGX) BTIg Research Upgrade From Neutral to Buy

$3.50

N/A
Infinity Pharmaceuticals (INFI) Morgan Stanley Reiterate Hold

$1

N/A
Ionis Pharmaceuticals (IONS) Leerink Swann Reiterate Hold

$36

N/A
Impax Laboratories (IPXL) RBC Capital Markets Price Target Cut Sector Perform From $35 to $$30 N/A
Intra-Cellular Therapies (ITCI) Leerink Swann Reiterate Buy

$95

N/A
Jazz Pharmaceuticals (JAZZ) Leerink Swann Reiterate Buy

$202

N/A
Jazz Pharmaceuticals (JAZZ) Goldman Sachs Price Target Cut Buy From $196 to $195 N/A
Jazz Pharmaceuticals (JAZZ) Deutsche Bank Price Target Raised Buy From $155 to $158 N/A
Atyr Pharma (LIFE) JPMorgan Chase  Price Target Cut Overweight From $15 to $10 N/A
Lexicon Pharmaceuticals (LXRX) Needham & Company LLC Reiterate Buy N/A N/A
Seres Therapeutics (MCRB) Leerink Swann Reiterate Buy

$12

N/A
Medivation (MDVN) Maxim Group Price Target Set Buy

$76

N/A
Medivation (MDVN) BMO Capital Markets Reiterate Market Perform

$53

N/A
Merck & Co. (MRK) Sanford C. Bernstein Price Target Raised Outperform From $66 to $74

$70

Novavax (NVAX) FBR & Co. Price Target Set Buy

$17

N/A
Ocular Therapeutix (OCUL) JMP Securities Price Target Cut Outperform From $21 to $5.84 N/A
Omeros (OMER) Wedbush Reiterate Outperform

$56

N/A
Spark Therapeutics (ONCE) Cantor Fitzgerald Reiterate Buy

$94

N/A
Onconova Therapeutics (ONTX) Maxim Group Initiation Buy

$6

N/A
Opko Health (OPK) Oppenheimer Holdings Reiterate Market Perform N/A

$20

Perrigo (PRGO) JPMorgan Chase  Price Target Cut Hold From $105 to $90 N/A
Perrigo (PRGO) Northland Securities Downgrade From Outperform to Market Perform N/A N/A
Perrigo (PRGO) Deutsche Bank Price Target Cut Buy From $115 to $105 N/A
Perrigo (PRGO) Jefferies Group Price Target Cut Hold From $97 to $84 N/A
Perrigo (PRGO) Barclays Plc Price Target Cut Overweight From $120 to $110 N/A
Recro Pharma (REPH) Brean Capital Reiterate Buy

$28

N/A
Stellar Biotechnologies (SBOT) Maxim Group Price Target Set Buy

$7

N/A
Sagent Pharmaceuticals (SGNT) Deutsche Bank Downgrade From Buy to Hold N/A N/A
Sarepta Therapeutics (SRPT) Janney Montgonery Scott Reiterate Neutral

$30

N/A
Viking Therapeutics (VKTX) Laidlaw Price Target Cut Buy From $20 to $10 N/A
Viking Therapeutics (VKTX) Maxim Group Price Target Set Buy

$5

N/A
Valeant Pharmaceuticals International (VRX) RBC Capital Markets Reiterate Sector Perform

$31

N/A
Valeant Pharmaceuticals International (VRX) Guggenheim Reiterate Buy

$55

N/A
Valeant Pharmaceuticals International (VRX) Mizuho Reiterate Underperform N/A N/A
Versartis (VSAR) Canaccord Genuity Price Target Set Buy

$28

N/A
Versartis (VSAR) Citigroup Price Target Raised Buy From $17 to $23 N/A
Voyager Therapeutics (VYGR) Wedbush Reiterate Outperform

$36

N/A
Voyager Therapeutics (VYGR) Piper Jaffray Cos. Price Target Set Buy

$37

N/A
Zosano Pharma (ZSAN) Ladenburg Thalmann Downgrade From Buy to Neutral N/A N/A

No insider buys to report.

Keryx Biopharmaceuticals (KERX)- Greg Madison, President & CEO, sold 3244 shares in two separate transactions. Madison sold 1,622 shares at $4.22; and 1,622 shares at $4.22. Madison still owns 257,123 shares of KERX.

Xencor (XNCR)- John S Stafford III, a 10% owner, sold 30,500 shares in three separate transactions. Stafford sold 10,000 shares at $21.88; 10,500 shares at $21.73; and 10,000 shares at $22.01. Stafford still owns 5,226,740 shares of XNCR.

BioLineRx announced that it has promoted CFO Philip Serlin to CEO effective October 10. He succeeds Kinneret Savitsky, Ph.D., who will serve as a scientific advisor to the company through March 2017 before departing. The company also promoted Director of Finance and Reporting Mali Zeevi, CPA, to Chief Financial Officer effective October 10.

Antares Pharma (ATRS) CFO James Fickenscher has informed the company that he will resign effective September 4 to pursue other interests. VP, Finance and Corporate Controller Keith Muckenhim will serve as interim CFO, principal accounting officer and principal financial officer while the company completes its search for a permanent CFO.

Celldex Therapeutics (CLDX) announced that it has promoted Elizabeth Crowley to SVP, Chief Product Development Officer, a newly created position. Previously, she was SVP of Product Development, a role she had since joining the firm in 2009.

InVivo Therapeutics Holdings (NVIV) announced the appointment of Pamela Stahl to the newly created position of Chief Commercial Office effective September 14. Previously, she was with UnitedHealthcare as CEO, Community Health Plan of Wisconsin.

NYSE- Valeant Pharmaceuticals International (VRX) shares were among the major losers on the NYSE. The stock closed 10.36% lower.

NASDAQ- Kura Oncology (KURA) shares were among the major gainers on the NASDAQ. The stock closed 20.18% higher. Mesoblast (MESO) ended the day 18.01% higher. aTyr Pharma (LIFE) ended the day 8.42% higher. Neos Therapeutics (NEOS) shares were among the major losers on the NASDAQ. The stock ended the day 15.17% lower. Omeros (OMER) ended the day 11.66% lower. Collegium Pharmaceutical (COLL) ended the day 9.28% lower.

NYSEMKT- Palatin Technologies (PTN) shares were among the major movers on the NYSEMKT. The stock closed 2.93% lower.

OTC- Amarantus Bioscience Holdings (AMBS) shares were among the major movers on the OTC market. The stock closed 2.22% higher.

Company (Ticker) Short Interest as a % of Float % Change Days to Cover
Neogen (NEOG)

2.7%

-14.3%

6

Neos Therapeutics (NEOS)

11.3%

0.4%

13

Neothetics (NEOT)

8.3%

-12%

3

Neurocrine Biosciences (NBIX)

5.3%

-7.5%

6

NeuroDerm (NDRM)

4.8%

-1.9%

11

Nexvet Biopharma (NVET)

2%

-9.6%

34

Nivalis Therapeutics (NVLS)

0.6%

8.7%

7

Northwest Biotherapeutics (NWBO)

13.5%

-1.2%

17

Novavax (NVAX)

23.9%

-0.5%

15

NovoCure (NVCR)

9.3%

-11.5%

6